LPCN Stock Summary and Trading Ideas (Lipocine | NASDAQ:LPCN)

Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.

Lipocine trades on the NASDAQ stock market under the symbol LPCN.

As of May 14, 2024, LPCN stock price declined to $5.26 with 6,869 million shares trading.

LPCN has a beta of 1.41, meaning it tends to be more sensitive to market movements. LPCN has a correlation of 0.06 to the broad based SPY ETF.

LPCN has a market cap of $28.13 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, LPCN stock traded as high as $32.13 and as low as $2.31.

The top ETF exchange traded funds that LPCN belongs to (by Net Assets): VTI, VXF, DFAT.

LPCN stock has underperformed the market in the last year with a return of +22.0%, while SPY returned +28.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LPCN shares. However, LPCN has outperformed the market in the last 3 month and 2 week periods, returning +32.2% and +11.2%, while SPY returned +5.8% and +2.1%, respectively. This indicates LPCN has been having a stronger performance recently.

LPCN support price is $4.91 and resistance is $5.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LPCN stock will trade within this expected range on the day.